BEIJING--(BUSINESS WIRE)--China Medical Technologies, Inc. (the “Company”) (NASDAQ: CMED), a leading China-based medical device company that develops, manufactures and markets high intensity focused ultrasound products and advanced in-vitro diagnostic systems, today announced that it has successfully completed the development of four liver fibrosis diagnostic reagents that use enhanced chemiluminescence immunoassay (“ECLIA”) technology. Upon introduction of these four new reagents in early 2007, China Medical’s total kit offering will increase to 62, which places the Company among the largest ECLIA reagent kit manufactures in China.
